Navigation Links
ThromboGenics Announces Half Year Results 2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.

During the first half of 2008, ThromboGenics has achieved a number of key milestones which have positioned the Company to successfully pursue the next stage of its corporate strategy. In this period, ThromboGenics signed a high value strategic alliance with Roche for its novel anti-cancer product TB-403 and has seen important new clinical data for its lead product, microplasmin, in patients with back of the eye disease. Given this progress, ThromboGenics is confident that the next twelve months will see further significant shareholder value being generated as it continues to maximise value from its product pipeline.
2008 highlights


- Major partnering deal: In June, ThromboGenics and its co-development

partner BioInvent signed a strategic alliance deal with Roche for its

novel anti-cancer agent, TB-403 (anti-PIGF). Under the terms of the

agreement ThromboGenics and BioInvent received an upfront payment of

EUR50 million and could potentially share up to EUR450 million in

milestone payments as well as double digit royalties. TB-403 is a novel

monoclonal antibody which blocks Placental Growth Factor (PIGF), one of

the growth factors responsible for the development of new blood

vessels. TB-403 is being developed as an anti-cancer agent, and is

currently in Phase I of clinical development. It acts by selectively

inhibiting tumor growth by blocking its blood supply without affecting

normal tissues.

Clinical Highlights

- TB-403 : Positive results announced in first Phase Ia study

with TB-403 and start of Phase Ib study in late stage cance

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
(Date:7/29/2015)... ... July 29, 2015 , ... Nearly everyone has heard of the ... people realize that a rich source of these cells is teeth—baby teeth that come ... need to be pulled to make room for braces. These potent stem cells ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new facility, ... tour and course will be given every Wednesday at 6pm to local interested veterinarians ... are welcome to attend with their veterinarian as well. Participants will be able to ...
(Date:7/28/2015)... 28, 2015 BioStructures, LLC, a privately ... a milestone of 4,000 implantations of Signafuse® Bioactive ... in early 2014 as a bone void filler ... procedures.  This is a distinguished status among recently ... of new synthetic products have received clearance with ...
Breaking Biology Technology:Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Revolutionary Bone Graft Exceeds Expectations 2
... June 24 NanoBio Corp. announced today,that it ... 15" list,designating NanoBio as one of the top ... FierceBiotech evaluated hundreds of privately held firms,based on ... of,technology, partnerships and competitive market position. NanoBio was,determined ...
... Inc., a,biopharmaceutical company engaged in the discovery and ... diseases, announced today,that it has been named to ... one of the top biotech companies of 2008. ... based on company,vision, revenue potential, quality of deals, ...
... Cardium Therapeutics,(Amex: CXM ) announced today that ... Microcap Index, according to the preliminary list of ... reconstitution of the,Russell Indexes will take place after ... (Logo: ), Annual reconstitution of ...
Cached Biology Technology:FierceBiotech Names NanoBio Corporation as One of the 'Fierce 15' Biotech Companies of 2008 2Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008 2Tolerx Named as One of the 'Fierce 15' Biotech Companies of 2008 3Cardium Selected for Inclusion in Russell Microcap Index 2Cardium Selected for Inclusion in Russell Microcap Index 3Cardium Selected for Inclusion in Russell Microcap Index 4
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... discovered new communication channels in underwater environments and ... channels, will be honored later this month by ... work will eventually allow multiple users and underwater ... faster and more reliably in complex underwater environments. ...
... that raise the risk of type 1 diabetes. As ... puzzle for this disease, the researchers expect to improve ... add to our knowledge of the biology of type ... genetic risk, we will be able to develop better ...
... The accumulation of fat in the liver as a result ... according to a new study with mice. The research found ... liver of mice fed alcohol and, at the same time, ... broken down. Chronic alcohol consumption causes fat to ...
Cached Biology News:NJIT professor's research suggests changes in underwater data communications 2Researchers continue to find genes for type 1 diabetes 2Resveratrol prevents fat accumulation in livers of 'alcoholic' mice 2
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
... for sizing single-stranded RNA ranging from 0.5 kb to ... ladder consists of nine bands in even increments (0.5 ... kb) to simplify size estimation. The 1.5 kb band ... orientation and identification of RNA bands on the gel. ...
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
Biology Products: